ArticleVaccines2023

Serologic Response and Safety after a Third Dose of the COVID-19 BNT162b2 Vaccine in Patients with Inflammatory Bowel Diseases.

Hadar Edelman-Klapper et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.